Description: Bucindolol (MJ-13105-1; MJ-131051) is a β-adrenergic receptor antagonist with the potential to be used for the treatment of chronic heart failure and atrial. Bucindolol is a fourth-generation β-blocker in development for the treatment of CHF. Bucindolol prevented new-onset AF; β1 and α(2c) polymorphisms predicted therapeutic response; and the 47% of patients who were β1389 Arg homozygotes had an enhanced effect size of 74%.

References: Black-Maier E, Steinberg BA, Piccini JP. Bucindolol hydrochloride in atrial fibrillation and concomitant heart failure. Expert Rev Cardiovasc Ther. 2015 Jun;13(6):627-36. doi: 10.1586/14779072.2015.1031111. Epub 2015 May 11. Review. PubMed PMID: 25959096.

Related CAS#: 71119-11-4 (free base) 70369-47-0 (HCl)

纯度：≥98%

CAS：71119-11-4